Treats clinically important hypotension resulting primarily from vasodilation in the…. ANDA 208905, held by Sandoz. Phenylephrine Hydrochloride.
As of Nov 16, 2026, ANDA 208905 (Phenylephrine Hydrochloride), held by Sandoz, was first approved by FDA on Jan 31, 2019, with 2 approved supplements and 0 published complete response letters.
Phenylephrine hydrochloride injection, is indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 31, 2019 | Original application | Approved | None posted |
| Phenylephrine Hydrochloride10MG/ML (10MG/ML) · solution;intravenous | Phenylephrine Hydrochloride | Rx |
| Phenylephrine Hydrochloride50MG/5ML (10MG/ML) · solution;intravenous | Phenylephrine Hydrochloride | Rx |
| Phenylephrine Hydrochloride100MG/10ML (10MG/ML) · solution;intravenous | Phenylephrine Hydrochloride | Rx |
| Jul 22, 2020 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jul 22, 2020 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jan 31, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters